pharmaphorum

JANUARY 24, 2022

A private equity group has agreed to take over most of IBM Watson Health, seven years after the business was launched with a pledge to revolutionise healthcare data analysis. For its part, IBM has said that the Watson for Oncology product has been improving year-on-year as the AI crunches more and more data.

Cerner 111

Cerner 111

Pharmaceutical Technology

JULY 27, 2022

of the companies included in our analysis recruiting for at least one such position. Robotics is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 17.2% in May 2022. in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 13, 2022

of the companies included in our analysis recruiting for at least one such position. Digitalization is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 47.3% in May 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 4, 2022

of the companies included in our analysis recruiting for at least one such position. Cloud is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 40.2% in May 2022. in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

NOVEMBER 8, 2022

of the companies included in our analysis recruiting for at least one such position. Internet of things is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was lower than the 17.3% in September 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JUNE 23, 2022

of the companies included in our analysis recruiting for at least one such position. Robotics is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 19.7% in April 2022. in May 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

The proportion of pharmaceutical companies hiring for industrial automation related positions rose in August 2022 compared with the equivalent month last year, with 52% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 49.7% in July 2022. in August 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

AUGUST 10, 2022

of the companies included in our analysis recruiting for at least one such position. Industrial automation is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 48.8% in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

AUGUST 8, 2022

of the companies included in our analysis recruiting for at least one such position. Future of work is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 42.9% in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

AUGUST 3, 2022

of the companies included in our analysis recruiting for at least one such position. Internet of things is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 14.6% in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 20, 2022

of the companies included in our analysis recruiting for at least one such position. Internet of things is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 15.8% in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

JULY 11, 2022

of the companies included in our analysis recruiting for at least one such position. Digital media is one of the topics that GlobalData, from whom our data for this article is taken, have identified as being a key disruptive force facing companies in the coming years. This latest figure was higher than the 41.4% in May 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Roots Analysis

JANUARY 28, 2024

Big Data in healthcare refers to the vast amount of data that is continuously expanding and cannot be efficiently stored or processed using traditional tools. Within the healthcare sector, structured data includes demographic details, vital indicators (like, height, weight, blood pressure, blood glucose).

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Hospitals 40

Pharmaceutical Technology

DECEMBER 15, 2022

In an expanded version of the sales forecast from GlobalData’s June 2022 publication, Cardiomyopathies: Global Drug Forecast and Market Analysis , the global cardiomyopathies market is expected to grow from $3.07bn last year to $9.63bn in 2031. The second highest contributing market is APAC, generating 33.2%

52

52

Pharmaceutical Technology

JUNE 29, 2022

In a series of data-driven deep dives, we will examine how the development of orphan drug therapies has evolved over the years, and use the FDA’s orphan drug program as a barometer of these advances. During 2001–10, the number of granted designations almost tripled, with 1,527 drugs receiving their first orphan drug designation.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Sickle cell disease is an inherited blood disorder that is caused by mutations in the HBB gene, which codes for the oxygen-carrying protein haemoglobin in red blood cells.

FDA 59

FDA 59

pharmaphorum

FEBRUARY 16, 2021

In this first draft guidance NICE raised a series of issues with Zynteglo, which bluebird has already agreed to supply at a confidential discount from its hefty price tag, which is around €1.57 NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5% million in Europe.

72

72

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

52

52

PharmaShots

MARCH 9, 2023

She developed various mobile technologies and pioneered early electronic labels including NFC tags, which helped Thin Film Electronics win the Wall Street Innovation Award and the Global Technology Award. She is an expert in trial design, strategy, and data analysis. LinkedIn Total experience: 16 yrs.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

DECEMBER 2, 2020

The FDA had already granted fast-track designation to the combination therapy, allowing extra help during the development process on the basis of earlier clinical data. TG said it expects the data submission to be complete in the first half of 2021.

FDA 52

FDA Chemotherapy 52

European Pharmaceutical Review

NOVEMBER 10, 2022

Improved analysis pre-clinically via advanced light microscopy could help. Their spatial and high-resolution capabilities provide a unique analysis tool to understand the complexity of those medicines, from their drug loading to the mechanism of action. Ex vivo tissue analysis. Figure 2 ). Physical characterisation.

Labelling 96

Labelling Compounding 96

Pharmaceutical Technology

JANUARY 27, 2023

Over the last few years, as price tags for drugs have continuously increased, the popularity of risk sharing agreements has been increasing at a rate of 24% annual average growth. Furthermore, he said extracting data to validate the criteria for a warranty reimbursement could be an onerous process.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

ISPE

JANUARY 9, 2023

The necessary paradigm shift will allow companies to predict deviations more accurately, perform root cause analysis (RCA), ensure data integrity and GxP compliance, and ultimately be more competitive in a highly regulated industry. From a User-Centric to a Data-Centric Model The foundations of a CPV 4.0 are discussed.

Documentation 52

Documentation Communication 52

European Pharmaceutical Review

DECEMBER 27, 2023

Important reassurance about CAR T-cell therapy came with the real-world data that emerged from both large single centres and various consortiums, which included data from both adult and paediatric patients in Israel and Europe. This is in addition to its considerable price tag. US Food and Drug Administration. Cytotherapy.

Adverse Reactions 83

Adverse Reactions Immunization Medical Schools Chemotherapy 83

Pharmaceutical Technology

MARCH 17, 2023

Watt said risk sharing agreements in oncology made up almost 50% of all pharmaceutical risk sharing agreements, as per a GlobalData analysis. Watt illustrated this through data, showing that PD-1/PD-L1 inhibitors have become the main oncology drug type that receives risk sharing agreements, making up 31% of the space.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. More data needed.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Several other treatments, like Novo Nordisk’s CagriSema (semaglutide + cagrilintide), are expected to follow after showing encouraging Phase II data. In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. More data needed.

Insurance 98

Insurance Labelling Communication FDA 98